Monitoring osteoporosis treatment: DXA should not be routinely repeated

American Family Physician

Volumn 82, Issue 7, 2010, Pages 752-754

  Muncie, Herbert ^a   Leblanc, Leanne L ^a  

^a LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

BONE DENSITY; DUAL ENERGY X RAY ABSORPTIOMETRY; EDITORIAL; FRACTURE; HIGH RISK POPULATION; HUMAN; LIFESTYLE MODIFICATION; OSTEOPOROSIS; PATIENT MONITORING; PRACTICE GUIDELINE; PREDICTION; RESISTANCE TRAINING; RISK ASSESSMENT; RISK REDUCTION; TREATMENT PLANNING; TREATMENT RESPONSE; DRUG MONITORING; FEMALE; METHODOLOGY; PATIENT COMPLIANCE; PHOTON ABSORPTIOMETRY; RADIOGRAPHY; STANDARD;

ABSORPTIOMETRY, PHOTON; BONE DENSITY CONSERVATION AGENTS; DRUG MONITORING; FEMALE; HUMANS; MEDICATION ADHERENCE; OSTEOPOROSIS;

EID: 78149489612     PISSN: 0002838X     EISSN: 0002838X     Source Type: Journal    
DOI: None     Document Type: Editorial

References (31)

1. Roux C, Garnero P, Thomas T, Sabatier JP, Orcel P, Audran M; Comité Scientifique du GRIO. Recommendations for monitoring antiresorptive therapies in postmenopausal osteoporosis. Joint Bone Spine. 2005;72(1):26-31.
2. Bonnick SL. Monitoring changes in bone density. Womens Health (Lond Engl). 2008;4:89-97.
3. Clowes JA, Peel NF, Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab. 2004;89(3):1117-1123.
4. Cramer JA, Silverman S. Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem. Am J Med. 2006;119(4 suppl 1):S12-S17.
5. Lewiecki EM. Nonresponders to osteoporosis therapy. J Clin Densitom. 2003;6(4):307-314.
6. Hodgson SF, et al.; AACE Osteoporosis Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003 [published correction appears in Endocr Pract. 2004;10(1):90]. Endocr Pract. 2003;9(6):544-564.
7. Institute for Clinical Systems Improvement. Health care guideline: diagnosis and treatment of osteoporosis. http://www.icsi.org/osteoporosis/diagnosis_and_treatment_of_osteoporosis__3.html. Accessed July 10, 2009.
8. Lenchik L, Kiebzak GM, Blunt BA; International Society for Clinical Densitometry Position Development Panel and Scientific Advisory Committee. What is the role of serial bone mineral density measurements in patient management? J Clin Densitom. 2002;5(suppl):S29-S38.
9. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285(6):785-795.
10. Clinician's guide to prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation; 2008. http://www.nof.org/professionals/pdfs/NOF_ClinicianGuide2009_v7.pdf. Accessed July 10, 2009.
11. Osteoporosis clinical guideline for prevention and treatment. National Osteoporosis Guidelines Group; 2008. http://www.iofbonehealth.org/health-professionals/national-regional-guidelines/references.html#ef_12. Accessed May 9, 2010.
12. North American Menopause Society. Management of postmenopausal osteoporosis: position statement of the North American Menopause Society. Menopause. 2002;9(2):84-101.
13. Brown JP, Josse RG; Scientific Advisory Council of the Osteoporosis Society of Canada. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada [published corrections appear in CMAJ. 2003;168(4):400, CMAJ. 2003;168(6):676, and CMAJ. 2003;168(5):544]. CMAJ. 2002;167(10 suppl):S1-S34.
14. Nelson HD, Morris CD, Kraemer DF, et al. Osteoporosis in postmenopausal women: diagnosis and monitoring. Evidence Report/Technology Assessment No. 28. AHRQ Publication No. 01-E031. Rockville, Md.: Agency for Healthcare Research and Quality. January 2001. http://www.ahrq.gov/clinic/epcsums/osteosum.htm. Accessed May 9, 2010.
15. Kolta S, et al. Follow-up of individual patients on two DXA scanners of the same manufacturer. Osteoporosis Int. 2000;11(8):709-713.
16. El Maghraoui A, Roux C. DXA scanning in clinical practice. QJM. 2008;101(8):605-617.
17. Cummings SR, Palermo L, Browner W, et al.; Fracture Intervention Trial Research Group. Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. JAMA. 2000;283(10):1318-1321.
18. Morton V, Torgerson DJ. Regression to the mean: treatment effect without the intervention. J Eval Clin Pract. 2005;11(1):59-65.
19. Bell KJ, Hayen A, Macaskill P, et al. Value of routine monitoring of bone mineral density after starting bisphosphonate treatment: secondary analysis of trial data. BMJ. 2009;338:b2266.
20. Berger C, Langsetmo L, Joseph L, et al.; Canadian Multicentre Osteoporosis Study Research Group. Change in bone mineral density as a function of age in women and men and association with the use of antiresorptive agents. CMAJ. 2008;178(13):1660-1668.
21. Cummings SR, Karpf DB, Harris F, et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med. 2002;112(4):281-289.
22. Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab. 2002;87:1586-1592.
23. Harris ST, Watts NB, Genant HK, et al.; Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA. 1999;282(14):1344-1352.
24. Reginster J, Minne HW, Sorensen OH, et al.; Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporosis Int. 2000;11(1):83-91.
25. Chapurlat RD, Palermo L, Ramsay P, Cummings SR. Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention Trial. Osteoporosis Int. 2005;16(7):842-848.
26. Watts NB, Cooper C, Lindsay R, et al. Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk. J Clin Densitom. 2004;7(3):255-261.
27. Watts NB, Geusens P, Barton IP, Felsenberg D. Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD. J Bone Miner Res. 2005;20(12):2097-2104.
28. Koval PG, Easterling L, Pettus D, Mackler L, Gottschall AB. Clinical inquiries. How should a DEXA scan be used to evaluate bisphosphonate therapy for osteoporosis? J Fam Pract. 2005;54(1):65, 69-71.
29. Hillier TA, Stone KL, Bauer DC, et al. Evaluating the value of repeat bone mineral density measurement and prediction of fractures in older women: the study of osteoporotic fractures. Arch Intern Med. 2007;167(2):155-160.
30. Compston J. Monitoring bone mineral density during antiresorptive treatment for osteoporosis. BMJ. 2009;338:b1276.
31. Curtis JR, Xi J, Westfall AO, et al. Improving the prediction of medication compliance: the example of bisphosphonates for osteoporosis. Med Care. 2009;47(3):334-341.